Detailed mode of action of the MTHFD1/2 inhibitor TH9619 now published in Nature Metabolism
The One-carbon Therapeutics team is proud and excited to share our latest paper published inNature Metabolism describing the detailed mode of action of our potent MTHFD1/2 inhibitorTH9619 under development for difficult-to-treat cancers. It explains the inhibitor’s cancer specificityand emphasises the importance of utilising correct human-like conditions and cancer models in drugdevelopment. We show that cancer-specific […]
We are presenting our novel MTHFD1/2 inhibitor at the DDR inhibitor summit
We are presenting our data at the DDR inhibitor summit, January 24 – 26, 2023, Boston, USWe are excited to hear about the newest progress in the DDR field and look forward to all interestingdiscussions.
One-carbon Therapeutics receives US patent
We are happy to announce that on the 22nd of November 2022 One-carbon Therapeutics received confirmation from the US patent office that a key patent covering the company’s leading drug candidate for the treatment of cancers, inflammation, autoimmune diseases has been granted. The granting of this patent establishes our strong IP portfolio and lays the […]
We are presenting at Bio-Europe 2022, October 24–26, Leipzig, Germany
We look forward to meeting you in person and sharing updates on our progress in bringing innovative medicine to the clinic and providing new options for cancer patients.
One-carbon therapeutics wins ELAVITY Pitch Event
Our team is happy and proud to have been voted as the winner for pitching our MTHFD1/2 inhibitor program. https://www.linkedin.com/feed/update/urn:li:activity:6948268990171365376
One-carbon therapeutics presents at Bio€quity 2022.
CEO Ana Slipicevic present the MTHFD2 program and one-carbon therapeutics AB in the Hot Topic session at Bio€quity 2022 in Milan.
Pitch prize in Bordeaux
The MTHFD2 program is pitched by CEO Dr Ana Slipicevic at the Meet2Win conference in Bordeaux and wins a pitch price!
Vinnova grants one-carbon therapeutics money
One-carbon therapeutics AB is granted 3,000,000 SEK from Sweden’s innovation agency Vinnova under the Medtech4Health and SweLife programs for further development of the MTHFD2 program.
MTHFD2 inhibitors now published in Nature Cancer
We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication stress, which is a hallmark for DNA damage response (DDR) inhibitors and placing our […]
One-carbon therapeutics appoints Dr Ana Slipicevic as acting CEO
We are very pleased to announce that Dr Ana Slipicevic has been appointed as acting CEO of one-carbon therapeutics AB. Ana is joining us from Oncopeptides AB where she has been translational research director and leading a team developing and implementing translational research strategies in the early and late-stage clinical trial pipeline. Dr Ana Slipicevic […]
